Consistent mutation status within histologically heterogeneous lung cancer lesions.

Item

http://www.wikidata.org/entity/Q54520483

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@en

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@nl

type

Item

label

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@en

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@nl

prefLabel

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@en

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@nl

P1476

Consistent mutation status within histologically heterogeneous lung cancer lesions.

@en

P2093

Johan Botling

http://www.w3.org/2001/XMLSchema#string

Juliana Imgenberg-Kreuz

http://www.w3.org/2001/XMLSchema#string

Karolina Edlund

http://www.w3.org/2001/XMLSchema#string

Patrick Micke

http://www.w3.org/2001/XMLSchema#string

P2860

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Screening for epidermal growth factor receptor mutations in lung cancer

A fluid cover medium provides superior morphology and preserves RNA integrity in tissue sections for laser microdissection and pressure catapulting.

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice

New driver mutations in non-small-cell lung cancer.

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.

Pulmonary preneoplasia--sequential molecular carcinogenetic events.

Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

P304

744-748

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2559.2012.04245.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Johanna Sofia Margareta Mattsson

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22458769

http://www.w3.org/2001/XMLSchema#string